Waltham, Massachusetts (PRWEB) June 06, 2023 OpenClinica proudly announces CEO Cal Collins is speaking at the DIA 2023 Global Annual Meeting in Boston,
Crappy trials are an innovation problem politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.
email article
Sleep medicine specialists are worried about a draft technology assessment from the Agency for Healthcare Research and Quality (AHRQ) that casts doubt on the long-term clinical benefit for the gold standard treatment for sleep apnea.
Reviewers found that studies of continuous positive airway pressure (CPAP) have consistently failed to show improvements in non-sleep-related outcomes linked to obstructive sleep apnea (OSA), such as stroke, heart attack, diabetes, and depression.
The report online at the AHRQ website and open for public comment through April 23 concluded that the published evidence mostly does not support that CPAP prescription affects long-term, clinically important outcomes, and it highlighted research gaps and methodological weaknesses in the available studies, along with significant CPAP compliance issues, which have all contributed to the failure to show long-term benefits for the treatment.